Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Intravitreal infliximab for choroidal neovascularization in patients refractory to conventional treatments.
[von hippel-lindau disease]
The
aim
of
the
study
is
to
evaluate
the
effectiveness
and
safety
of
intravitreal
infliximab
in
the
course
of
compassionate
use
in
patients
affected
by
choroidal
neovascularization
.
This
prospective
interventional
case
series
includes
four
eligible
patients
,
affected
by
exudative
age-related
macular
degeneration
(
2
/
4
)
,
retinal
angiomatous
proliferation
(
1
/
4
)
and
central
retinal
vein
occlusion
(
1
/
4
)
,
who
were
refractory
to
conventional
treatments
.
The
patients
received
a
single
intravitreal
injection
of
0
.
05
ml
of
reconstituted
infliximab
solution
(
20
mg
/
ml
)
.
The
main
outcomes
measure
were
changes
in
best-corrected
visual
acuity
and
central
retinal
thickness
.
Patients
were
evaluated
at
baseline
,
every
week
for
the
first
month
,
then
every
two
weeks
,
and
on
demand
.
Morphologic
parameters
improved
after
a
single
infliximab
intravitreal
injection
.
However
,
all
patients
developed
acute
uveitis
in
a
period
ranging
from
4
to
7
weeks
after
treatment
.
Control
of
the
intraocular
inflammation
was
achieved
with
topical
and
systemic
steroids
in
3
patients
,
whereas
in
one
case
pars
plana
vitrectomy
was
needed
.
A
single
intravitreal
injection
of
infliximab
does
not
seem
to
improve
the
natural
history
of
CNV
from
different
aetiologies
.
However
,
all
patients
in
our
series
developed
a
serious
inflammatory
response
that
required
surgical
management
in
one
case
.
The
intravitreal
administration
of
infliximab
is
hence
not
safe
and
not
recommended
in
clinical
practice
.
Diseases
Validation
Diseases presenting
"single intravitreal injection"
symptom
coats disease
von hippel-lindau disease
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom